EyePoint Pharmaceuticals, Inc.
EYPT
$8.42
-$0.50-5.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.17% | -41.00% | 4.75% | -5.27% | -107.70% |
| Total Depreciation and Amortization | 6.42% | 14.46% | 12.71% | 19.47% | 170.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.50% | 10.95% | -20.46% | -42.24% | 284.77% |
| Change in Net Operating Assets | -1,222.61% | 92.99% | -576.55% | 122.94% | -16.63% |
| Cash from Operations | -48.18% | 8.15% | -93.42% | 35.27% | -34.89% |
| Capital Expenditure | 28.13% | 75.60% | -74.89% | 24.62% | -35.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 141.64% | -637.86% | 111.14% | -824.98% | 147.55% |
| Cash from Investing | 141.19% | -692.50% | 110.10% | -870.91% | 144.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.38% | 56.16% | -- | -- | -- |
| Issuance of Common Stock | -99.61% | 1,162.72% | 1,827.04% | -86.29% | -97.91% |
| Repurchase of Common Stock | -- | 100.00% | 0.00% | 98.21% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 20.27% | -- | 100.00% | -144.94% | -147.22% |
| Cash from Financing | -100.63% | 1,175.41% | 3,514.89% | 186.09% | -99.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -173.19% | 281.68% | 93.93% | -1,658.48% | -106.92% |